Big Pharma Split Corp Class A - Asset Resilience Ratio

Latest as of June 2025: 89.67%

Big Pharma Split Corp Class A (PRM) has an Asset Resilience Ratio of 89.67% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Big Pharma Split Corp Class A's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CA$23.10 Million
≈ $16.71 Million USD Cash + Short-term Investments

Total Assets

CA$25.77 Million
≈ $18.64 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Big Pharma Split Corp Class A's Asset Resilience Ratio has changed over time. See PRM equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Big Pharma Split Corp Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PRM stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CA$0.00 0%
Short-term Investments CA$23.10 Million 89.67%
Total Liquid Assets CA$23.10 Million 89.67%

Asset Resilience Insights

  • Very High Liquidity: Big Pharma Split Corp Class A maintains exceptional liquid asset reserves at 89.67% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Big Pharma Split Corp Class A Industry Peers by Asset Resilience Ratio

Compare Big Pharma Split Corp Class A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Metrics Master Income Trust
AU:MXT
Asset Management 0.14%
Northern Trust Corporation
NASDAQ:NTRS
Asset Management 6.11%
Principal Financial Group Inc
NASDAQ:PFG
Asset Management 8.30%
Industrivarden AB ser. C
ST:INDU-C
Asset Management 0.16%
Sprott Physical Gold and Silver Trust
TO:CEF
Asset Management 99.66%
Anxin Trust Co Ltd
SHG:600816
Asset Management 36.21%
Norte Grande
SN:NORTEGRAN
Asset Management 0.00%
Sprott Inc.
TO:SII
Asset Management 1.84%

Annual Asset Resilience Ratio for Big Pharma Split Corp Class A (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Big Pharma Split Corp Class A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 95.71% CA$25.17 Million
≈ $18.21 Million
CA$26.30 Million
≈ $19.03 Million
+93.01pp
2023-12-31 2.71% CA$718.24K
≈ $519.56K
CA$26.53 Million
≈ $19.19 Million
-57.98pp
2022-12-31 60.69% CA$23.73 Million
≈ $17.16 Million
CA$39.10 Million
≈ $28.28 Million
-32.71pp
2021-12-31 93.40% CA$35.32 Million
≈ $25.55 Million
CA$37.81 Million
≈ $27.35 Million
-4.29pp
2020-12-31 97.69% CA$22.40 Million
≈ $16.21 Million
CA$22.93 Million
≈ $16.59 Million
+0.80pp
2019-12-31 96.89% CA$26.33 Million
≈ $19.05 Million
CA$27.18 Million
≈ $19.66 Million
-1.66pp
2018-12-31 98.55% CA$33.14 Million
≈ $23.98 Million
CA$33.63 Million
≈ $24.33 Million
+5.66pp
2017-12-31 92.89% CA$30.18 Million
≈ $21.83 Million
CA$32.49 Million
≈ $23.50 Million
--
pp = percentage points

About Big Pharma Split Corp Class A

TO:PRM Canada Asset Management
Market Cap
$11.89 Million
CA$16.44 Million CAD
Market Cap Rank
#26612 Global
#1095 in Canada
Share Price
CA$13.52
Change (1 day)
-2.10%
52-Week Range
CA$10.71 - CA$15.50
All Time High
CA$15.50
About

Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.